


Bioorthogonal Imaging of Aurora Kinase A in Live Cells**

Katherine S. Yang, Ghyslain Budin, Thomas Reiner, Claudio Vinegoni, and Ralph Weissleder*



Cell division (mitosis) is a tightly controlled process that is coordinated and regulated by a network of proteins localized in the nucleus. The key stages of mitosis are centrosome maturation, chromosome condensation, nuclear envelope breakdown, centrosome separation, bipolar spindle formation, chromosome separation, and finally cytokinesis.^[1] Aurora kinase A (AKA) belongs to the Aurora kinase family of serine/threonine kinases, which have been shown to play critical roles in mitotic progression.^[1–4] During mitosis, AKA localizes to centrosomes during late S to early G2 phase. As the cell proceeds to metaphase, AKA localizes to the microtubules and near the spindle poles, where it remains until anaphase when it migrates to some extent to the spindle midzone. Finally, during cytokinesis, AKA localizes to the midbody.^[1,3–5] Whilst localized to these specific cellular regions, AKA interacts with and phosphorylates several intracellular targets, including p53, MBD3, and BRCA1, each of which are critical mediators of malignant transformation.^[1,5] The unique stage-specific nuclear and intracellular locations of AKA during mitosis thus make it an interesting imaging target.

AKA overexpression has been reported in the majority of epithelial cancers^[6] and has been shown to cause defects in cell division, such as centrosome amplification and abnormal spindle formation.^[7] An imbalance of AKA during mitosis may also alter the normal interactions between AKA and tumor suppressors such as p53, possibly promoting cell viability and tumorigenesis.^[7] Because of the link between AKA overexpression and tumorigenesis, the use of AKA small molecule inhibitors as potential therapeutics for cancer is now an area of great interest.^[6] For example, 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]-amino]benzoic acid (MLN8054) is an AKA-specific inhibitor that has about 100-fold greater selectivity for AKA over other kinases, and has been shown to result in mitotic arrest and apoptosis.^[8]

Despite interest in the involvement of AKA in cancer and the development of several AKA inhibitors, lack of specific

imaging agents has impaired our ability to visualize and quantify AKA expression directly, either in panels of live cells or in patient-derived primary cancer cells (e.g. circulating tumor cells or from fine needle aspirates). Consequently, owing to the challenge of designing such agents, imaging probes with appropriate AKA selectivity and kinetics thus remain extremely limited. Antibodies, for example, are largely ineffective since they rarely have adequate cell permeability. Other techniques that have been used to image AKA include the use of fixed cells and AKA-specific antibodies, or exogenous expression of fluorescently tagged AKA. Neither technique, however, enables accurate visualization of AKA in its endogenous state. The ability to visualize AKA within live cells, or even by way of whole body imaging, would not only provide new insights into the biology of AKA and its ideal pharmacological inhibition, but could also improve testing of the clinical efficacy of new small molecule AKA inhibitors. Herein, in a bid to address this need, we sought to develop small molecule AKA imaging agents using MLN8054 as a scaffold, together with a bio-orthogonal two-step labeling method.^[9,10] We initially modified the carboxylic acid of our MLN8054 precursor with *trans*-cyclooctene (TCO). The resulting compound (MLN8054-TCO; **13**) was cell-membrane permeable and, upon binding its target, could be visualized using a bioorthogonal tetrazine (Tz)-labeled fluorophore.^[11] We thus report the first use of MLN8054-TCO (**13**) as an imaging agent for AKA in live cells and as a tool for quantifying cellular AKA expression.

To design the modification of MLN8054 with TCO, we used the crystal structure of AKA in complex with MLN8054 (PDB ID 2X81).^[12] Analysis indicated that modification of the carboxylic acid group would be the most viable side of the molecule for derivatization since it extends toward the solvent. MLN8054 was synthesized as described previously with a minor modification (Scheme 1).^[13] Briefly, ortholithiation of the 4-chloro-*N*-Boc-aniline with *tert*-butyl lithium, followed by addition of 2,6-difluorobenzoyl chloride, yielded the benzophenone derivative **1**. After aniline deprotection and conversion of the amine **2** into an iodide **3**, a Sonogashira coupling was performed with an *N*-Boc propargylamine (prepared following a described procedure)^[13] affording the alkyne **4**. The amine group of **4** was then deprotected under acidic conditions, followed by treatment with base, to allow the direct intramolecular cyclization to form the azepinone ring **5**. Compound **6** was formed by treating **5** with *N,N*-dimethylformamide dimethyl acetal in refluxing toluene. The pyrimidinoazepine **7** (MLN8054) was prepared by treating the enaminone **6** with 4-guanidinobenzoic acid in refluxing ethanol in the presence of potassium carbonate. The carboxylic acid **7** was then coupled to a piperidine derivative **10** (prepared in three steps from the 4-(*N*-Boc-amino)piperidine) affording compound **11** in 79% yield. Finally, the amino protective group was removed and the resulting primary amine was treated with TCO-NHS, furnishing MLN8054-TCO (**13**) with an overall yield of 6% in ten steps (Scheme 1). Cycloaddition of MLN8054-TCO (**13**) to Texas Red-tetrazine (TR-Tz) was initially investigated by mixing the two compounds (0.25 mM), stirring for two minutes, and analyzing the products by HPLC-MS. These spectra confirmed the quanti-

[*] Dr. K. S. Yang,^[†] Dr. G. Budin,^[†] Dr. T. Reiner, Dr. C. Vinegoni, Prof. R. Weissleder


Center for Systems Biology, Massachusetts General Hospital
185 Cambridge Street, Boston, MA 02114 (USA)
E-mail: rweissleder@mgh.harvard.edu

Prof. R. Weissleder
Harvard Medical School
200 Longwood Avenue, Boston, MA 02115 (USA)

[†] These authors contributed equally to this work.

[**] This work was supported by the National Institutes of Health (NIH) grant number RO1EB010011 and P50CA086355. K.Y. was supported by an NIH grant T32-CA079443 and T.R. was supported by a grant from the German Academy of Sciences Leopoldina (LPDS 2009-24). We thank Prof. Peter Sorger and Dr. Robert Yang for assistance with cellWoRx and ImageRail and Paolo Fumene Feruglio for assistance with image processing. We also thank Dr. Jonathan Carlson, Dr. Greg Thurber, and Dr. Carlos Tassa for helpful input and discussions about the manuscript.

Supporting information for this article (experimental details) is available on the WWW under <http://dx.doi.org/10.1002/anie.201200994>.



Scheme 1. Synthetic scheme of MLN8054-TCO (**13**). Boc = *tert*-butoxycarbonyl; THF = tetrahydrofuran; TFA = trifluoroacetic acid; DCM = dichloromethane; Ms = methanesulfonyl; TEA = triethanolamine; DMF = dimethylformamide; HBTU = *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate; DIPEA = *N,N*-diisopropylethylamine; NHS = *N*-hydroxysuccinimide.

tative conversion of TR-Tz into the cycloaddition product MLN8054-TR (Figure S1).

The inhibitory effects of MLN8054 (**7**), MLN8054-TCO (**13**), TR-Tz, and the pre-treated MLN8054-TR on AKA were evaluated using a kinase activity assay (see Supporting Information). The IC_{50} value of MLN8054 (**7**) was 1.5 nM. Analysis of MLN8054-TCO (**13**) resulted, as expected, in a lower, but still acceptable, IC_{50} value of 61.8 nM (Figure S2 and Table S1). In contrast, the pre-treated fluorescent MLN8054-TR had an affinity of only 437.3 nM (Figure S2 and Table S1), which supported the use of the two-step labeling method for imaging. Given the reasonable enzyme affinity achieved with MLN8054-TCO (**13**), we sought to image AKA within cells. This imaging was performed in two separate experiments, in which: 1) AKA was tagged in live cells with MLN8054-TCO (**13**) followed by TR-Tz treatment, and then imaged in fixed cells, and 2) AKA was tagged in live cells with MLN8054-TCO (**13**) followed by treatment with a membrane-permeable carboxyfluorescein diacetate-Tz, and then imaged in live cells.

To investigate colocalization between AKA and the bioorthogonal small molecule in fixed cells, we designed pancreatic cancer cells (PANC-1) to express a green fluorescent protein (GFP)/AKA fusion protein (GFP-AKA). Cells were first incubated for 20 minutes with MLN8054-TCO

(**13**) in growth medium (1.5 μM , 0.1 % DMSO). Excess probe was washed out and TR-Tz was added in the growth medium for 20 minutes (1 μM , 0.1 % DMSO). Cells were fixed for DNA staining with Hoechst dye and imaged with a DeltaVision deconvolution microscope (Figure 1). GFP-AKA localized to the microtubules near the spindle poles during metaphase, as previously reported^[3] (Figure 1a). As predicted, we observed a very similar microtubule localization of the small-molecule MLN8054-TCO (**13**), as revealed by reaction with TR-Tz (Figure 1b). Subsequent merging of the GFP-AKA and MLN8053-TCO (**13**) images, in addition to Hoechst staining (Figure 1c), revealed significant colocalization of the GFP and Texas Red signals (yellow, Figure 1d). Control experiments verified that neither TR-Tz nor the pre-treated compound MLN8054-TR exhibit significant fluorescent staining in PANC-1 tumor cells (Figure S3). These experiments not only demonstrate the low background signal of the fluorophore but also highlight the advantage of the bioorthogonal approach over a directly conjugated drug-fluorophore pair (Figure S3). When unlabeled MLN8054 (**7**) was used, no significant staining was observed with TR-Tz (Figure S3B). Given the unique spatial localization of AKA during mitosis, we next determined whether it would be possible to image its distribution using the bioorthogonal approach. Accordingly, after treating PANC-1 cells as above,




Figure 1. Colocalization of MLN8054-TCO (**13**)/TR-Tz with GFP-AKA. PANC-1 Tet-On cells were incubated for 20 min with 1.5 μ M MLN8054-TCO (**13**), washed, and incubated for 20 min with 1 μ M Texas Red-Tz for bioorthogonal reaction inside the cells. 40 \times images collected by deconvolution microscopy. a) GFP-AKA localization in PANC-1 cells, b) MLN8054-TCO (**13**)/TR-Tz staining, c) Hoechst staining of fixed nuclei, d) merge. Scale bar: 10 μ m.

we found equally good colocalization of the two dyes during different stages of the G2/M phase (Figure S4). Interestingly, GFP-AKA expression and MLN8054-TCO (**13**) staining were both significantly reduced in interphase, a period when AKA is not significantly expressed (Figure S4A).^[2,3] The results also demonstrated that bioorthogonal chemistry within live cells is possible and is sufficiently fast and selective under biological conditions.

We next determined whether the two-step AKA imaging procedure could be applied to other cancer cell lines. To compare small molecule AKA imaging to standard AKA antibody staining (which requires fixed cells), we selected eight cancer cell lines (HeLa, PANC-1, A549, SKOV-3, MDA-MB-231, U-87 MG, SW480, and MIA PaCa-2) and two normal cell lines (IMR-90 and HEK-293). Cells were plated in duplicate in 96-well plates and were treated with MLN8054-TCO (**13**) then TR-Tz, as described above. Each well was imaged at 10 \times magnification to examine the entire population of cells. The fluorescence intensity for both the AKA antibody channel and the Texas Red channel were then determined separately using ImageRail software.^[14] As shown in Figure 2a, antibody staining revealed that each normal and cancer cell line expressed different levels of AKA. Similar variations in AKA expression levels were likewise detected following the small molecule two-step labeling procedure, with good correlation (Figure 2a and b, $R^2 = 0.93$).

While the feasibility experiments described above were performed using fixed cells, our ultimate goal was to develop a method in which AKA could be imaged in live cells. Unfortunately, cellular uptake of Texas Red (and its Tz derivatives) was found to be limited in intact live cells




Figure 2. Expression of AKA in ten cell lines measured using MLN8054-TCO (**13**). Cell lines were plated in duplicate in 96-well plates 48 hr prior to assay. Cells were first incubated with 1.5 μ M MLN8054-TCO (**13**) for 20 min (0.1% DMSO). After washing, cells were incubated with 1 μ M TR-Tz (0.1% DMSO). Following washing, cells were fixed and processed for staining with an α -AKA antibody and Hoechst. Integrated fluorescence intensity was measured by imaging at 10 \times with a cellWoRX microscope (Applied Precision). a) Percent maximum signal of the integrated intensity for each cell line was calculated for the TRITC channel (MLN8054-TCO (**13**)/TR-Tz) and the FITC channel (AKA antibody) using ImageRail software.^[14] b) Correlation between the percent maximum signal for the AKA antibody (x-axis) and MLN8054-TCO (**13**)/TR-Tz (y-axis). Data were fit by linear regression using GraphPad (Prism), with an $R^2 = 0.93$. Data represent at least two independent experiments.

(Figure S5). Rather, TR-Tz appears to enter live cells through endocytosis. The bright, punctate staining emanating from the endocytic vesicles likely served to mask the localization of TR-Tz to MLN8054-TCO (**13**)/AKA, as observed following fixation/permeabilization/washing in the fixed cell scenario described above. To identify alternative fluorophores suitable for live cell imaging, we screened a library of various Tz-modified fluorophores to determine which might exhibit diffusion-mediated cellular uptake. Ten dyes with an emission wavelength in the red or green spectral region were chosen (Figure S5). For this experiment, we also engineered a PANC-1 cell line to stably express mCherry-AKA (RFP-AKA) so as to visualize dyes emitting in the green spectral region. With the notable exception of carboxyfluorescein diacetate-Tz (CFDA-Tz), most fluorophore-Tz dyes tested showed lower accumulation in live cells. Boron-dipyrromethene (BODIPY)-Tz and nitrobenzoxadiazole (NBD)-Tz also showed some colocalization with AKA but at the expense of higher background signals; on account of this, they were not pursued further (Figure S5).




Figure 3. Activation properties of CFDA-Tz. Left: Activation of CFDA fluorescence by esterases in the cell lysate. a) CFDA-Tz dye ($20\text{ }\mu\text{M}$) was incubated at room temperature with HT1080 cell lysate (0, 1, 2.5, 5, 10, or $20\text{ }\mu\text{g}$). Fluorescence emission was recorded at 526 nm over time; b) Emission spectrum of CFDA-Tz before and after activation by lysate. CFDA-Tz dye ($20\text{ }\mu\text{M}$) was incubated with HT1080 cell lysate (0 or $10\text{ }\mu\text{g}$) for 40 min at room temperature. The fluorescence emission scan was then recorded.

Carboxyfluorescein diacetate (CFDA) is a nonfluorescent, cell-permeable dye, activated by nonspecific cellular esterases.^[15] For these experiments, we chose to synthesize a Tz conjugate of this dye and evaluate its activation properties in cell lysates. CFDA-Tz was incubated with varying amounts of HT1080 cell lysate, and the fluorescence from activated




Figure 4. Live cell colocalization of MLN8054-TCO (**13**)/CFDA-Tz in PANC-1 Tet-On cells expressing RFP-AKA. PANC-1 cells were incubated for 30 min with 125 nM MLN8054-TCO (**13**). Cells were washed and incubated for 30 min with 187.5 nM CFDA-Tz for bioorthogonal reaction inside living cells. After washing, cells were incubated for 10 min with DRAQ5 to stain nuclei in live cells. $40\times$ images with 1.6 zoom were collected by deconvolution microscopy. a) PANC-1 cellular localization of RFP-AKA, b) MLN8054-TCO (**13**)/CFDA-Tz staining, c) DRAQ5 staining of nuclei, d) merge. Scale bar: $10\text{ }\mu\text{m}$.

CFDA was measured at 526 nm (Figure 3 a). Hydrolysis of the acetate moieties was rapid, reaching a plateau after only 60 minutes of incubation with $20\text{ }\mu\text{g}$ of cell lysate. While decreasing the quantity of cell lysate slowed the kinetics of activation, the same signal plateau was reached after a few hours. Without cell lysate, the dye remained in its native state. The fluorescent signal before and after activation was shown to increase by a factor of approximately ten (Figure 3 b).

We subsequently investigated the use of CFDA-Tz in the two-step labeling procedure, using the red fluorescent protein (RFP)/AKA fusion (RFP-AKA) PANC-1 cell line. Live cells were imaged in a warm, humidified imaging chamber equipped with a microscope. RFP-AKA was seen to localize to centrosomes and microtubules/spindles during metaphase of mitosis (Figure 4 a). A strikingly similar localization was observed for MLN8054-TCO (**13**)/CFDA-Tz (Figure 4 b). Merging these images together, along with the DRAQ5 DNA stain, again demonstrated a high degree of colocaliza-




Figure 5. Localization of MLN8054-TCO (**13**)/CFDA-Tz in dividing HT1080 H2B-Apple cells. HT1080 cells were incubated for 30 min with 125 nM MLN8054-TCO (**13**), washed and incubated for 30 min with $1\text{ }\mu\text{M}$ CFDA-Tz for bioorthogonal reaction inside living cells. Following 2 h of washing, live cells at different stages of mitosis were imaged at $40\times$ with 1.6 zoom by deconvolution microscopy. Left column: MLN8054-TCO (**13**)/CFDA-Tz, Middle column: H2B-Apple, Right column: merge. a) Interphase, b) Prophase, c) Prometaphase, d) Metaphase, e) Anaphase, f) Telophase, g) Cytokinesis. Scale bar: $10\text{ }\mu\text{m}$.

tion (Figure 4c,d). Control experiments were performed using an HT1080 fibrosarcoma cell line stably transfected with H2B-Apple (a red fluorescent protein), to enable easy identification of actively dividing cells. These experiments served to further demonstrate that neither CFDA-Tz nor the pre-treated compound MLN8054-CFDA exhibit significant fluorescent staining in tumor cells (Figure S6). Labeling of endogenous AKA in live cells with MLN8054-TCO (**13**)/CFDA-Tz during different stages of the G2/M phase was also examined using the HT1080 H2B-Apple cell line (Figure 5). In this experiment, MLN8054-TCO (**13**)/CFDA-Tz showed very good correlation with the expected localization of AKA during mitosis. Overall, our results not only show that the MLN8054-TCO (**13**) bioorthogonal two-step labeling procedure is useful for labeling fixed cells, but also demonstrate that this technique can be used to label targets for imaging in living cells.

In conclusion, we show that endogenous AKA can be imaged in live cells by way of a two-step bioorthogonal reaction. As an imaging agent, MLN8054-TCO (**13**) in combination with CFDA-Tz demonstrated superior selectivity, fast reaction kinetics, and a sufficient target-to-background ratio to enable AKA visualization. These results build on previous studies that have used two-step bioorthogonal imaging approaches to visualize both cell surface^[16] and cytoplasmic targets.^[11,17,18] This technique is an important step towards designing agents for imaging AKA at the whole-body level, for example, for positron emission tomography or for use with near-infrared optical imaging techniques. We believe that the described strategy for bioorthogonal labeling of a cell cycle-specific intracellular/nuclear target will likely enable the labeling of other intracellular targets. Furthermore, we expect that this approach will allow us to also examine how labeled AKA drugs behave and interact not only in live cells but also within the tumor microenvironment of mice.

Received: February 6, 2012

Published online: May 29, 2012

Keywords: aurora kinase · cancer · cell cycle · cycloaddition · live cell imaging

- [1] T. Marumoto, D. Zhang, H. Saya, *Nat. Rev. Cancer* **2005**, 5, 42.
- [2] G. Vader, S. M. Lens, *Biochim. Biophys. Acta Rev. Cancer* **2008**, 1786, 60.
- [3] M. Carmena, W. C. Earnshaw, *Nat. Rev. Mol. Cell Biol.* **2003**, 4, 842.
- [4] A. R. Barr, F. Gergely, *J. Cell Sci.* **2007**, 120, 2987.
- [5] R. D. Carvajal, A. Tse, G. K. Schwartz, *Clin. Cancer Res.* **2006**, 12, 6869.
- [6] S. M. Lens, E. E. Voest, R. H. Medema, *Nat. Rev. Cancer* **2010**, 10, 825.
- [7] J. Fu, M. Bian, Q. Jiang, C. Zhang, *Mol. Cancer Res.* **2007**, 5, 1.
- [8] M. G. Manfredi et al., *Proc. Natl. Acad. Sci. USA* **2007**, 104, 4106.
- [9] M. L. Blackman, M. Royzen, J. M. Fox, *J. Am. Chem. Soc.* **2008**, 130, 13518.
- [10] N. K. Devaraj, R. Weissleder, S. A. Hilderbrand, *Bioconjugate Chem.* **2008**, 19, 2297.
- [11] N. K. Devaraj, S. Hilderbrand, R. Upadhyay, R. Mazitschek, R. Weissleder, *Angew. Chem.* **2010**, 122, 2931; *Angew. Chem. Int. Ed.* **2010**, 49, 2869.
- [12] D. A. Sloane et al., *ACS Chem. Biol.* **2010**, 5, 563.
- [13] T. T. Denton, X. Zhang, J. R. Cashman, *J. Med. Chem.* **2005**, 48, 224.
- [14] B. L. Millard, M. Niepel, M. P. Menden, J. L. Muhlich, P. K. Sorger, *Nat. Methods* **2011**, 8, 487.
- [15] B. Rotman, B. W. Papermaster, *Proc. Natl. Acad. Sci. USA* **1966**, 55, 134.
- [16] N. K. Devaraj, R. Upadhyay, J. B. Haun, S. A. Hilderbrand, R. Weissleder, *Angew. Chem.* **2009**, 121, 7147; *Angew. Chem. Int. Ed.* **2009**, 48, 7013.
- [17] T. Reiner, S. Earley, A. Turetsky, R. Weissleder, *ChemBioChem* **2010**, 11, 2374.
- [18] G. Budin, K. S. Yang, T. Reiner, R. Weissleder, *Angew. Chem.* **2011**, 123, 9550; *Angew. Chem. Int. Ed.* **2011**, 50, 9378.